Suchergebnisse - "Shitara, K"

PubPharm (103)

1

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer

enthalten in: ESMO open | 2024

von Shitara, K. | Fleitas, T. | Kawakami, H. | +29

2

Corrigendum to "Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer" : [ESMO Open 8 (2023) 100762

enthalten in: ESMO open | 2024

von Kubota, Y. | Kawazoe, A. | Mishima, S. | +9

ErratumFor: ESMO Open. 2023 Feb;8(1):100762. - PMID 36610262

3

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer

enthalten in: ESMO open | 2023

von Kubota, Y. | Kawazoe, A. | Mishima, S. | +9

CommentIn: ESMO Open. 2023 Apr;8(2):100778. - PMID 36791669

4

Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer

enthalten in: ESMO open | 2022

von Van Cutsem, E. | Hochster, H. | Shitara, K. | +11

5

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)

enthalten in: ESMO open | 2022

von Okamoto, W. | Sakai, K. | Makiyama, A. | +16

6

Response to the letter to the Editor : TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2021

von Shitara, K. | Lunceford, J.

CommentOn: Ann Oncol. 2021 Sep;32(9):1127-1136. - PMID 34082019

7

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2021

von Shitara, K. | Özgüroğlu, M. | Bang, Y. | +15

CommentIn: Ann Oncol. 2021 Sep;32(9):1073-1074. - PMID 34216739

8

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer : an exploratory subgroup analysis from the TAGS study

enthalten in: ESMO open | 2021

von Tabernero, J. | Shitara, K. | Zaanan, A. | +11

9

Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma : results from the randomised phase III KEYNOTE-062 study

enthalten in: ESMO open | 2021

von Van Cutsem, E. | Valderrama, A. | Bang, Y. | +11

10

Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer : the randomized phase III ACHIEVE-2 trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2021

von Yamazaki, K. | Yamanaka, T. | Shiozawa, M. | +17

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]